Portal vein thrombosis and outcomes for pediatric liver transplant candidates and recipients in the United States
dc.contributor.author | Waits, Seth A. | en_US |
dc.contributor.author | Wojcik, Brandon M. | en_US |
dc.contributor.author | Cai, Shijie | en_US |
dc.contributor.author | Mathur, Amit K. | en_US |
dc.contributor.author | Englesbe, Michael J. | en_US |
dc.date.accessioned | 2011-11-10T15:36:03Z | |
dc.date.available | 2012-11-02T18:56:46Z | en_US |
dc.date.issued | 2011-09 | en_US |
dc.identifier.citation | Waits, Seth A.; Wojcik, Brandon M.; Cai, Shijie; Mathur, Amit K.; Englesbe, Michael J. (2011). "Portal vein thrombosis and outcomes for pediatric liver transplant candidates and recipients in the United States ." Liver Transplantation 17(9): 1066-1072. <http://hdl.handle.net/2027.42/87010> | en_US |
dc.identifier.issn | 1527-6465 | en_US |
dc.identifier.issn | 1527-6473 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/87010 | |
dc.description.abstract | The effect of occlusive portal vein thrombosis (PVT) on the mortality of pediatric liver transplant candidates and recipients is poorly defined. Using standard multivariate techniques, we studied the relationship between PVT and waiting‐list and posttransplant survival rates with data from the Scientific Registry of Transplant Recipients (September 2001 to December 2007). In all, 5087 liver transplant candidates and 3630 liver transplant recipients were evaluated during the period. PVT was found in 1.4% of the liver transplant candidates (n = 70) and in 3.7% of the liver transplant recipients (n = 136). PVT was not associated with increased wait‐list mortality [hazard ratio (HR) = 1.1, 95% confidence interval (CI) = 0.5‐2.4, P = 0.77]. Conversely, PVT patients had a significantly lower unadjusted survival rate in the posttransplant period ( P = 0.01). PVT was independently associated with increased posttransplant mortality in multivariate models (30‐day survival: HR = 2.9, 95% CI = 1.6‐5.3, P = 0.001; overall survival: HR = 1.7, 95% CI = 1.1‐2.4, P = 0.01). The presence of PVT in pediatric liver candidates was not associated with increased wait‐list mortality but was clearly associated with posttransplant mortality, especially in the immediate postoperative period. Liver Transpl 17:1066–1072, 2011. © 2011 AASLD. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Portal vein thrombosis and outcomes for pediatric liver transplant candidates and recipients in the United States | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Surgery, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | University of Michigan Health System, 2926 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109‐0331 | en_US |
dc.identifier.pmid | 21744467 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/87010/1/22371_ftp.pdf | |
dc.identifier.doi | 10.1002/lt.22371 | en_US |
dc.identifier.source | Liver Transplantation | en_US |
dc.identifier.citedreference | Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736 – 741. | en_US |
dc.identifier.citedreference | Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587 – 591. | en_US |
dc.identifier.citedreference | Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 2007; 7: 34. | en_US |
dc.identifier.citedreference | Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, et al. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg 2002; 235: 292 – 296. | en_US |
dc.identifier.citedreference | Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49: 720 – 724. | en_US |
dc.identifier.citedreference | Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, et al. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 2008; 30: 415 – 419. | en_US |
dc.identifier.citedreference | Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 12: 2115 – 2119. | en_US |
dc.identifier.citedreference | Orloff MJ, Orloff MS, Orloff SL, Girard B. Portal vein thrombosis in cirrhosis with variceal hemorrhage. J Gastrointest Surg 1997; 1: 123 – 130. | en_US |
dc.identifier.citedreference | Egawa H, Tanaka K, Kasahara M, Takada Y, Oike F, Ogawa K, et al. Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl 2006; 12: 1512 – 1518. | en_US |
dc.identifier.citedreference | Gerbes AL. The patient with refractory ascites. Best Pract Res Clin Gastroenterol 2007; 21: 551 – 560. | en_US |
dc.identifier.citedreference | Schettino GC, Fagundes ED, Roquete ML, Ferreira AR, Penna FJ. Portal vein thrombosis in children and adolescents. J Pediatr (Rio J) 2006; 82: 171 – 178. | en_US |
dc.identifier.citedreference | Chardot C, Herrera JM, Debray D, Branchereau S, De Dreuzy O, Devictor D, et al. Portal vein complications after liver transplantation for biliary atresia. Liver Transpl Surg 1997; 3: 351 – 358. | en_US |
dc.identifier.citedreference | Al‐Holou S, Mathur AK, Ranney D, Kubus J, Englesbe MJ. Survival among children with portal vein thrombosis and end‐stage liver disease. Pediatr Transplant 2010; 14: 132 – 137. | en_US |
dc.identifier.citedreference | Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010; 16: 999 – 1005. | en_US |
dc.identifier.citedreference | Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: 2537 – 2546. | en_US |
dc.identifier.citedreference | Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010; 16: 83 – 90. | en_US |
dc.identifier.citedreference | Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010; 123: 111 – 119. | en_US |
dc.identifier.citedreference | Ravindra KV, Guthrie JA, Woodley H, Davison S, McClean P, Prasad KR, Stringer MD. Preoperative vascular imaging in pediatric liver transplantation. J Pediatr Surg 2005; 40: 643 – 647. | en_US |
dc.identifier.citedreference | Yu CY, Concejero AM, Huang TL, Chen TY, Tsang LL, Wang CC, et al. Preoperative vascular evaluation in living donor liver transplantation for biliary atresia. Transplant Proc 2008; 40: 2478 – 2480. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.